Efficacy, Safety, and Immunogenicity of Vaccines against Viruses: From Network Medicine to Clinical Experimentation
This reprint emerges as a beacon guiding researchers, scientists, and medical professionals through uncharted territories. In this volume, we delve deep into the intricate world of immunization, where the fusion of bioinformatics and network medicine reshapes our understanding of vaccines' effi...
Saved in:
| Other Authors: | , , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_128720 | ||
| 005 | 20231130 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20231130s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-9232-9 | ||
| 020 | |a 9783036592336 | ||
| 020 | |a 9783036592329 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-9232-9 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 072 | 7 | |a PSB |2 bicssc | |
| 100 | 1 | |a Guzzi, Pietro Hiram |4 edt | |
| 700 | 1 | |a Milano, Marianna |4 edt | |
| 700 | 1 | |a Das, Jayanta Kumar |4 edt | |
| 700 | 1 | |a Guzzi, Pietro Hiram |4 oth | |
| 700 | 1 | |a Milano, Marianna |4 oth | |
| 700 | 1 | |a Das, Jayanta Kumar |4 oth | |
| 245 | 1 | 0 | |a Efficacy, Safety, and Immunogenicity of Vaccines against Viruses: From Network Medicine to Clinical Experimentation |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (204 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This reprint emerges as a beacon guiding researchers, scientists, and medical professionals through uncharted territories. In this volume, we delve deep into the intricate world of immunization, where the fusion of bioinformatics and network medicine reshapes our understanding of vaccines' efficacy, safety, and immunogenicity. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 650 | 7 | |a Biochemistry |2 bicssc | |
| 653 | |a monkeypox | ||
| 653 | |a mpox | ||
| 653 | |a MPXV | ||
| 653 | |a universal vaccine | ||
| 653 | |a multi-epitope mRNA vaccine | ||
| 653 | |a immunoinformatics | ||
| 653 | |a influenza | ||
| 653 | |a H3N2 | ||
| 653 | |a antigenic distance | ||
| 653 | |a hemagglutinin | ||
| 653 | |a attribute network embedding | ||
| 653 | |a herpes simplex virus | ||
| 653 | |a HSV-2 | ||
| 653 | |a vaccine | ||
| 653 | |a costimulation | ||
| 653 | |a genital | ||
| 653 | |a antibodies | ||
| 653 | |a T cells | ||
| 653 | |a MDV | ||
| 653 | |a chickens | ||
| 653 | |a Th17 cells | ||
| 653 | |a IL-17A | ||
| 653 | |a interferon-gamma and adaptive immunity | ||
| 653 | |a adenoviral vector | ||
| 653 | |a cell fusion | ||
| 653 | |a human endogenous retrovirus type W (HERV-W) | ||
| 653 | |a R-peptide | ||
| 653 | |a Syncytin-1 | ||
| 653 | |a HIV | ||
| 653 | |a PLWH | ||
| 653 | |a ART | ||
| 653 | |a vaccination | ||
| 653 | |a immune responses | ||
| 653 | |a CD4 | ||
| 653 | |a COVID-19 | ||
| 653 | |a HPV | ||
| 653 | |a respiratory syncytial virus | ||
| 653 | |a RSV | ||
| 653 | |a mucosal vaccine | ||
| 653 | |a inactivated vaccine | ||
| 653 | |a low-energy electron irradiation | ||
| 653 | |a LEEI | ||
| 653 | |a PC formulation | ||
| 653 | |a PCLS | ||
| 653 | |a binding antibody assay | ||
| 653 | |a immune correlates of protection | ||
| 653 | |a modified treatment policy | ||
| 653 | |a neutralizing antibody assay | ||
| 653 | |a principal stratification | ||
| 653 | |a principal surrogate | ||
| 653 | |a SARS-CoV-2 | ||
| 653 | |a stochastic intervention | ||
| 653 | |a stochastic interventional vaccine efficacy | ||
| 653 | |a peste des petits ruminants | ||
| 653 | |a ewes | ||
| 653 | |a lambs | ||
| 653 | |a passive immunity | ||
| 653 | |a quadrivalent adjuvanted influenza vaccines | ||
| 653 | |a toll-like receptors | ||
| 653 | |a CVID | ||
| 653 | |a azoximer bromide | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/8184 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/128720 |7 0 |z DOAB: description of the publication |